Viridian Therapeutics公司高管在电话会议中透露,其用于治疗甲状腺眼病的药物Lumvoa,五次输注疗程的定价方案,与竞争对手安进公司旗下药物Tepezza的八次标准输注疗程总价大致相当。这一价格策略旨在为市场提供更具成本效益的治疗选择。
Viridian Therapeutics公司高管在电话会议中透露,其用于治疗甲状腺眼病的药物Lumvoa,五次输注疗程的定价方案,与竞争对手安进公司旗下药物Tepezza的八次标准输注疗程总价大致相当。这一价格策略旨在为市场提供更具成本效益的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.